Background: Currently, there is limited documentation on adverse reactions associated with generic fixed-dose combination antidiabetic drugs. Aim: The aim of this study was to report the incidental finding of drowsiness associated with brand substitution of a fixed-dose glibenclamide/metformin combination tablet. Methods: A prospective cross-over study was conducted among 84 patients previously treated with a stable dose of 320 mg gliclazide coadministered with 2000 mg metformin. Patients were switched to two tablets twice daily of originator or generic fixeddose glibenclamide 2.5 mg/metformin 500 mg for 12 weeks. After 12 weeks, patients who received originator fixed-dose glibenclamide/metformin were switched to generic tablets, whereas patients who had received generic tablets were switched to originator tablets. Both groups were subsequently followed-up for another 12 weeks. Results: Six patients (7.14%) experienced drowsiness with generic fixed-dose glibenclamide/metformin but not with the originator tablets. The patients complained of being unable to perform normal activities unless they had a nap. Blood glucose levels during these symptoms in four of the patients were between 8.3 and 9.4 mmol/L. There were no significant changes in fasting plasma glucose (FPG) or HbA1c levels in any of the affected patients. One patient had a 9.3-mmol/L decrease in FPG, but the HbA1c was still within the normal range. Conclusion: The cases of drowsiness with generic fixed-dose glibenclamide/metformin were unlikely to be associated with hypoglycaemia.
INTRODUCTION
Fixed-dose glibenclamide/metformin is a combination tablet for the treatment of type 2 diabetes mellitus (T2DM) that consists of two drug classes, namely a sulphonylurea (glibenclamide) and a biguanide (metformin). The main concern with the use of sulphonylureas is hypoglycaemia occurring with blood glucose levels of around or below 3.8 mmol/L. 1 Drowsiness is one of the neuroglycopenic symptoms of hypoglycaemia when the blood glucose threshold is around 2.3-3.1 mmol/L, leading to impaired cognitive abilities. 2 However, hyperglycaemia may also present with symptoms of drowsiness and tiredness. 3 Another blood glucose parameter that may predict both hypoglycaemic and hyperglycaemic states is HbA1c. The HbA1c level, which depicts long-term glycaemic control, was weighted to the most recent month. It reflects the average blood sugar level for the past two to three months. HbA1c has been shown to be correlated with afternoon (pre-and post-lunch) and evening (pre-dinner, post-dinner and bedtime) plasma glucose. 4 Hence, HbA1c levels can reflect plasma glucose levels, particularly levels in the afternoon and evening. This is in contrast with fasting plasma glucose (FPG) levels, which reflect the morning glucose level. High HbA1c may reflect a persistent hyperglycaemic state, whereas low HbA1c may indicate frequent episodes of hypoglycaemia.
A patient's body weight and any concomitant drugs are factors that may also cause drowsiness. Excess body weight, which is a risk factor for T2DM, is associated with tiredness. 5 In addition, most T2DM patients are overweight or obese, which, in turn, may lead to drowsiness. 6 Drowsiness can also be induced by medicines such as beta-blockers. 7 Drowsiness can have profound effects on a patient's quality of life and activities of daily living. Currently, there is a lack of information on patients who experience drowsiness with originator or generic glibenclamide/metformin. In this paper we report on the incidental finding of increased rates of drowsiness in a study assessing the efficacy and adherence of patients with brand substitution between originator (Glucovance; Merck, Semoy, France) and a locally manufactured generic glibenclamide/metformin (Diamide; Hovid, Ipoh, Malaysia). Diamide has fulfilled the Malaysian bioequivalent requirement, 8 which was based on a 90% confidence interval of the whole tablet as a component over the reference (originator brand) and allowed variation in the rate and extent of absorption within a limit of 80-125%.
METHODS
A prospective cross-over single-blind interventional study was conducted in the Out Patient Department, Hospital Pulau Pinang, Malaysia, from September 2014 to August 2015. Ethics approval for the study was granted by the Medical Research Ethics Committee (MREC), Ministry of Health, Malaysia. The intervention in this study consisted of changing gliclazide coadministered with metformin to originator (Glucovance) or generic (Diamide) glibenclamide 2.5 mg/metformin 500 mg, two tablets twice daily. It was hoped that the overall reduction in tablet burden may improve adherence. The medical records of T2DM patients were screened using the systematic sampling method to assess the eligibility of patients for inclusion in the study. In all, 89 T2DM patients aged >18 years who had previously been treated with a stable dose of 320 mg/day gliclazide coadministered with 2000 mg/day metformin were approached and included in the study after providing written informed consent. Patients were randomly divided into two groups using a stratified randomisation method to receive either originator or generic glibenclamide/metformin for 12 weeks. Five patients withdrew from study and 84 patients completed the initial 12 weeks with originator (n = 43 patients) or generic (n = 41 patients) glibenclamide/metformin. After 12 weeks, patients who had initially received originator were switched to the generic formulation, whereas those who had received the generic formulation were switched to the originator for another 12 weeks. A glucometer (Freestyle Lite; Abbott, Alameda, CA, USA) and a self-monitoring blood glucose (SMBG) booklet were provided to all patients. Patients were advised to check and record their blood glucose level if they experienced symptoms of hypoglycaemia. Drowsiness was the unexpected self-reported adverse drug reaction (ADR) during the study period. The investigators did not ask patients specifically whether they had experienced drowsiness. Because this is a subjective measure, patients were advised to check their blood glucose level whenever they felt drowsy. The drowsiness was identified and reported using a standard form to report a suspected ADR to the Ministry of Health Malaysia. The Naranjo probability scale 9 was used to assess the level of causality of ADR including both pharmacological and non-pharmacological causes of drowsiness. The present study only involved two physicians who were in charge of treating the patients and two pharmacists who dispensed the patients' medication. The physicians were blinded to the treatment arm, whereas the patients and the pharmacist were not blinded. Weight, height, HbA1c and FPG were measured at baseline and again at 12 and 24 weeks. There were three treatment visits at Weeks 0, 12 and 24. In addition, the patients were reviewed for adverse effects, symptoms of hypoglycaemia and had their SMBG records checked at 4-weekly intervals during drug refills throughout the study.
Normally distributed data are presented as the mean AE SD, whereas categorical data are presented as the number of patients in each group.
RESULTS
There was no significant difference between the two groups of patients at baseline in terms of demographic characteristics, duration of diabetes, glycaemic control, body mass index (BMI), comorbidities and concomitant medications. Mean patient age was 58.01 AE 7.87 years and the mean duration of diabetes was 12.68 AE 7.70 years. Mean HbA1c and FPG at baseline were 8.38 AE 0.77% and 8.57 AE 2.28 mmol/L, respectively. No patient experienced any haemolytic anaemia or blood transfusion during the duration of the study.
Six patients experienced drowsiness with generic glibenclamide/metformin, but none experienced drowsiness with originator glibenclamide/metformin ( Table 1 ). The patients who experienced drowsiness did not have a history of drowsiness when taking gliclazide coadministered with metformin. Five patients who switched from gliclazide coadministered with metformin to generic glibenclamide/metformin experienced daily drowsiness after the therapy was started for 1 day ( Table 1 ). The investigators became aware of this unexpected adverse event after two patients who were on generic glibenclamide/metformin complained of drowsiness during their drug refill visit in Week 4, and another three patients subsequently self-reported drowsiness after taking generic glibenclamide/metformin. Nevertheless, this ADR was not present when the therapies were changed to originator glibenclamide/metformin after 12 weeks. The drowsiness resolved the following day after the switch. One patient who was initially randomised to originator glibenclamide/metformin had no complaint of drowsiness. After 12 weeks, she was switched to the generic formulation and experienced drowsiness the day after the switch. All six affected patients complained of decreased productivity and being unable to perform their usual activities even though they had sufficient sleep each night. The drowsiness occurred everyday and only subsided after having a nap 0.5-1 h, allowing them to continue with their daily activities. However, one patient claimed that she slept most of the time and was unable to perform household chores. During the symptoms, the SMBG readings were between 8.3 and 9.4 mmol/L among four of the patients (Table 1) . Another two patients did not perform SMBG, but there was no other symptom suggestive of hypoglycaemia. There were no clinically significant changes in FPG and HbA1c in any of the affected patients except for Patient no. 1, who had a 9.3-mmol/L decrease in FPG although HbA1c remained within the normal range ( Table 1) . Half of the patients (n = 3) who complained of drowsiness were prescribed beta-blockers, whereas another half (n = 3) were not.
Further statistical analyses comparing HbA1c, FPG, BMI, serum creatinine and the use of beta-blockers between these six patients and the 78 patients who did not experience drowsiness demonstrated no significant differences between the groups (Table 2) .
DISCUSSION
In the present study, 7.14% of patients experienced drowsiness with generic glibenclamide/metformin therapy that affected their ability to perform daily activities. However, this adverse reaction was not found Table 1 Demographic characteristics, time after ingestion to onset of drowsiness, self-monitored blood glucose levels during drowsiness, HbA1c and fasting plasma glucoses levels before and after treatment with the causal drug (generic glibenclamide/metformin) and drug production batch numbers Patient when the same subjects were prescribed originator glibenclamide/metformin. The Naranjo probability scale 9 was used to assess the level of causality of the ADR, with the result showing a probable (score of 2) relationship between the patients' drowsiness and the generic drug. The possibility of drowsiness induced by hypoglycaemia or hyperglycaemia was ruled out because the patients' SMBG levels at the time of drowsiness were slightly elevated from normal blood glucose control. HbA1c and FPG may not be predictors of drowsiness because there was no clinically significant difference between post-and pre-intervention HbA1c and FPG levels, and the levels were above the target range (Table 1) . Similarly, Fritschi et al. 3 reported that there was no significant relationship between fatigue and HbA1c or glucose variability. It was noted that there was a 9.3-mmol/L decrease in FPG levels in Patient no. 1. This may be attributed to the patient's age (a geriatric patient), and the drug excretion in this patient may have been slowed because creatinine clearance was reduced from 54 mL/min at baseline to 45 mL/min at the end of the study. However, overall, this patient's HbA1c was still within the normal range and there was no significant difference between the affected and unaffected patients with regard to HbA1c and serum creatinine. BMI and concomitant drug use were assessed in addition to blood glucose measurements in case they contributed to the episodes of drowsiness. Previous cross-sectional studies demonstrated that an increased in BMI was strongly associated with fatigue or tiredness, 3, 6 and these symptoms are also frequent adverse effects of beta-blockers. 7 There was no significant difference in BMI between the affected patients and those without any symptoms. Among the patients who experienced drowsiness, there was an equal distribution of these patients in the normal, pre-obese and obese BMI categories based on World Health Organization (WHO) guidelines. 10 Hence, the BMI may not be a possible explanation for the drowsiness. Indeed, the same patients did not experience drowsiness when receiving the originator glibenclamide/ metformin. The concomitant use of beta-blockers was unlikely the cause of drowsiness because three of the patients who experienced drowsiness were not prescribed beta-blockers. Meanwhile, the other three affected patients who were prescribed beta-blockers did not experience drowsiness when receiving the originator glibenclamide/metformin. In addition, there were no significant differences in the rates of beta-blockers use between affected and unaffected patients. The drowsiness cases were not associated with hypoglycaemia. Hence, the variation in bioavailability between the originator and generic glibenclamide/metformin was unlikely the reason behind the adverse reaction. However, there have been previous case reports of patients developing ADRs with generic drugs due to differences in the excipients between the originator and generic formulations. 11 The excipients in the originator Normally distributed data are presented as the mean AE SD. Categorical data are presented as the number of patients in each group. a Independent t-tests revealed no significant differences (p > 0.05). b Chi-squared tests revealed no significant differences (p > 0.05).
glibenclamide/metformin are microcrystalline cellulose, croscarmellose sodium, Povidone K-30 and magnesium stearate, 12 whereas the generic formulation contains propylene glycol, hydroxypropyl methylcellulose, polyvinylpyrrolidone, microcrystalline cellulose, magnesium stearate, sodium starch glycolate, pregelatinised starch, talc and isopropyl alcohol. 13 The differences in the excipients between the originator and generic glibenclamide/metformin formulations may be the reason for this unexpected adverse reaction. However, the present study was a single-blinded study in which the physicians were blinded to the treatment, but the patients were not; the patients knew whether they were taking the originator or generic glibenclamide/metformin and they may have perceived a lack of quality of the generic drug. Hence, future studies on a larger number of patients would be necessary to assess whether the use of generic glibenclamide/metformin could lead to a greater incidence of drowsiness.
CONCLUSION
Six of the 84 patients studied reported drowsiness when receiving generic glibenclamide/metformin but did not have such a problem when they were taking the originator brand. There was no association between drowsiness and blood glucose measurements, BMI or concomitant beta-blocker use. Clinicians and pharmacists should be alert and recognise possible ADRs during brand substitution of fixed-dose glibenclamide/metformin combination tablets.
